Microfluidic Reagent Screening for Aseptic In Vitro Transcription

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current manufacturing and formulation technologies for polynucleotide therapeutics, such as mRNA, are prone to contamination and degradation, and centralized production is costly and slow, making them unsuitable for therapeutic formulations and point-of-care operations.

Innovation Solution

A microfluidic system comprising a chip-receiving component, fluid processing assemblies, and a fluid communication pathway is used to facilitate rapid formulation of therapeutic compositions, minimizing contamination and enabling scalable production of single patient dosages through a closed path apparatus with automated processes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If centralized production is used for polynucleotide therapeutics, then manufacturing scale is improved, but production time increases and contamination risk worsens

Engineering Contradiction:

Improvemanufacturing scaleVSAvoidproduction time

Core Design Contradiction:

Quantity of substanceVSLoss of time

Solution Approach 1:

The system divides the manufacturing process into modular microfluidic chambers that can operate independently and in parallel. Each chamber performs a specific function (mixing, reaction, purification) allowing simultaneous processing of multiple samples, thereby increasing throughput without proportionally increasing overall process time

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention transitions from traditional large-scale centralized production to a distributed network of microfluidic devices that can be deployed at multiple locations including point-of-care settings. This spatial distribution enables parallel production across different dimensions, reducing total production time while maintaining scale

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

2Quantity of substance

If centralized production is used for polynucleotide therapeutics, then manufacturing scale is improved, but contamination risk increases

Engineering Contradiction:

Improvemanufacturing scaleVSAvoidcontamination risk

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The manufacturing process is segmented into isolated microfluidic chambers with controlled fluid pathways. Each chamber operates as an independent containment unit, limiting the spread of contamination. The system includes separate loading and unloading ports that maintain closed pathways throughout the process, reducing exposure to external contaminants

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The system employs disposable microfluidic cartridges or chips that are pre-assembled and sealed. These single-use components eliminate cross-contamination between batches and patients, as each cartridge is used once and then discarded, ensuring no carryover of contaminants while maintaining manufacturing scale through rapid cartridge replacement

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Ease of operation

If manual handling is increased for therapeutic formulation, then operational flexibility is improved, but contamination risk worsens

Engineering Contradiction:

Improveoperational flexibilityVSAvoidcontamination risk

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The system incorporates automated fluid handling, mixing, and dispensing mechanisms within the microfluidic device. Sensors detect fluid levels, mixing completion, and transfer readiness, automatically triggering the next step without manual intervention. This self-service capability maintains operational flexibility through programmable protocols while minimizing human contact that could introduce contaminants

Inventive Principle:

Principle #25Self-service

4Productivity

If microfluidic system is used for rapid formulation, then production speed is improved, but device complexity increases

Engineering Contradiction:

Improveproduction speedVSAvoiddevice complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The microfluidic device integrates multiple functions into a single platform: sample loading, reagent mixing, thermal cycling for PCR, in vitro transcription, purification, and product dispensing. This multi-functionality achieves rapid end-to-end production without requiring separate complex equipment for each step, balancing productivity gains with manageable device complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250297297A1Apparatus and method to screen reagents for in vitro transcription

Publication Date: 2025.09.25 MEDICI THERAPEUTICS INC

AI summary

A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip-receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.